Psoriasis and Psoriatic Arthritis Markets Undergo Big Changes as IL-17s, such as Novartis’ Cosentyx and Lilly’s Taltz, Increase Penetration
IL-17s stop Janssen’s Stelara in its tracks and while Cosentyx holds out as the only approved IL-17 in PsA, competition is looming – according to a recent study by Spherix Global Insights CAMBRIDGE, Mass., April 4, 2017 /PRNewswire/ — Spherix Global Insights has just released the results of two independent surveys of 200 rheumatologists and […]
RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis US 2017
The Multiple Sclerosis (MS) market has become fiercely competitive with the introduction of new disease-modifying therapies (DMTs) over the past several years and new therapies, such as Roche’s ocrelizumab, on the horizon. As physicians, patients and industry adapt to these changes, Spherix Global Insights examines the most sought after market, first line new patient starts, […]
Pre-launch Intentions for Sanofi-Regeneron’s Dupixent (dupilumab) Suggest Rapid Uptake in an Area of High Unmet Need
100% of surveyed dermatologists see a role for Dupixent in their practices with most anticipating quick adoption according to a recent independent study by Spherix Global Insight Download Report Overview March 29, 2017 – Cambridge, Massachusetts. The future treatment of atopic dermatitis got a whole lot brighter yesterday with the approval of Sanofi-Regeneron’s Dupixent, the […]
Roche Nabs FDA Approval for “Game-changing” Therapy for the Treatment of Multiple Sclerosis
The Q1 edition of RealTime Dynamix™: Multiple Sclerosis published by Spherix Global Insights finds that adoption of Ocrevus will be quick for patients with primary progressive multiple sclerosis, but uptake will be more muted in patients with relapsing forms of the disease Download Report Overview: Multiple Sclerosis Download Report Overview: DMT Switching in MS CAMBRIDGE, […]
The Battle for Preferred Alternative Mechanism Biologic in Crohn’s Disease Heats Up as Launch of Janssen’s Stelara Approaches the Six-Month Mark
While gastroenterologists report a strong intent to increase future prescribing, they are quite divided about whether Stelara will displace Takeda’s Entyvio as the alternate mechanism share leader, according to the latest report by Spherix Global Insights Download Report Overview March 20, 2017 – Cambridge, Massachusetts. Spherix Global Insights has released “RealTime Dynamix: Crohn’s Disease, Q1 […]
RealTime Dynamix™: Multiple Sclerosis Q1
The Multiple Sclerosis (MS) market is more dynamic and complex than ever with several disease-modifying therapies (DMTs) currently available and a potential game-changer entry, in the form of Roche/Genentech’s Ocrevus (ocrelizumab), approved by the FDA on March 28, 2017. RealTime Dynamix™: Multiple Sclerosis allows marketing professionals to keep abreast and react to these market changes […]
RealTime Dynamix™: Hyperkalemia (Neph) Q1
The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. […]
Will US Rheumatologists Follow in the Footsteps of Dermatologists for Adoption of Eli Lilly’s Taltz?
CAMBRIDGE, Mass., Jan. 26, 2017 /PRNewswire/ — A recent study of 100 surveyed US rheumatologists, reveals that after viewing a product profile for the likely second to market IL-17 inhibitor for PsA, 84% anticipate prescribing Lilly’s Taltz (ixekizumab), if approved. Furthermore, the vast majority of rheumatologists plan to initiate treatment within the first-year of launch. […]
Extended FDA Review for Lilly/Incyte’s Olumiant (baricitinib) in Rheumatoid Arthritis Delays Market Entry for First Major Competitor to Pfizer’s Xeljanz
And Sanofi-Regeneron’s IL-6 inhibitor, sarilumab, also getting back on track after receiving a Complete Response Letter from the FDA in October 2016. The competition to be the preferred first-line, non-TNF agent in the treatment RA is expected to be fierce in 2017, according to a new report from Spherix Global Insights Cambridge, Massachusetts. (PRWEB) January […]
Studies of the Multiple Sclerosis (MS) Market Highlight the Increasing Penetration of Oral Disease-modifying Therapies (DMTs) into First Line Position
ZUG, Switzerland, Jan. 17, 2017 /PRNewswire/ — The MS market has shifted over the course of 2016 according to the Q4 update of RealTime Dynamix™, an independent report based on survey responses of 100 US neurologists who actively manage patients with MS. According to the study, oral DMTs captured a significantly higher share at the […]
